N/A N=69 Randomized Triple-blind Prevention

The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults

Cardiovascular Diseases · Cardiovascular Abnormalities · Heart Attack · Stroke · Hypertension

Bottom Line

View on ClinicalTrials.gov: NCT03826914 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2020

Primary outcome: Primary: Change From Baseline of Total Cholesterol After 90 Days — -0.57; -1.09 mmol/L — p=0.042

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: CardioFlex Q10 (Dietary_supplement); Placebo (Dietary_supplement)
Age: Adult, Older Adult · 30+ yrs
Sex: All
Sponsor: University of Manitoba
Primary completion: Jun 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline of Total Cholesterol After 90 Days	-0.57; -1.09	0.042 sig
SECONDARY Heart Rate Variability	3.49; -6.27	0.04 sig

Summary

Cardiovascular diseases (CVD), primarily heart disease and stroke, are the leading causes of death and prescription drug use in Canada. Research on certain dietary supplements looks promising as a way to help reduce CVD risk factors. Studies show that supplementation of certain nutrients such as antioxidants, amino acids, electrolytes, vitamins and minerals may effectively reduce cardiovascular risk factors. The dietary supplement CardioFlex Q10, which is high in the aforementioned components, was developed to help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation. The overall objective of this study is to determine if 90 days of supplementing with CardioFlex Q10 can reduce CVD risk factors in adults, independent of other dietary or physical activity changes.

Eligibility Criteria

Inclusion Criteria

Age 30-65
An accelerated plethysmograph (APG) type (biological age of arteries) of D, E, F or G and/or a high density lipoprotein (HDL) to total cholesterol (TC) ratio of ≤24 percent

Exclusion Criteria

Have used prescription cholesterol or blood pressure medication in the last 3 months
Perform more then 150 minutes of moderate to rigorous activity per week
Pregnant or planning on getting pregnant during the study period

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03826914). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.